Ernexa Therapeutics Inc. Proceeds from Issuance of Private Placement
Ernexa Therapeutics Inc. (ERNA) had Proceeds from Issuance of Private Placement of $11.00 million as of 2022-03-09, per its 10-Q filed 2022-07-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2022-07-01
- Ernexa Therapeutics Inc. proceeds from issuance of private placement for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
- Ernexa Therapeutics Inc. proceeds from issuance of private placement for fiscal 2013 was $2.34M.
- Ernexa Therapeutics Inc. proceeds from issuance of private placement for fiscal 2012 was $0.00.
| Period end | Proceeds from Issuance of Private Placement | Proceeds from Issuance of Private Placement 12 month |
|---|---|---|
| 2022-03-09 | $11.00M 10-Q · filed 2022-07-01 | |
| 2014-12-31 | $0.00 10-K · filed 2015-03-27 | |
| 2013-12-31 | $2.34M 10-K · filed 2015-03-27 | |
| 2012-12-31 | $0.00 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |